journal
MENU ▼
Read by QxMD icon Read
search

Neurology® Neuroimmunology & Neuroinflammation

journal
https://www.readbyqxmd.com/read/28105460/validity-of-a-pcr-assay-in-csf-for-the-diagnosis-of-neurocysticercosis
#1
Arturo Carpio, Alfredo Campoverde, Matthew L Romo, Lorena García, Luis M Piedra, Mónica Pacurucu, Nelson López, Jenner Aguilar, Sebastian López, Luis C Vintimilla, Ana M Toral, Pablo Peña-Tapia
OBJECTIVE: To prospectively evaluate the validity of a PCR assay in CSF for the diagnosis of neurocysticercosis (NC). METHODS: We conducted a multicenter, prospective case-control study, recruiting participants from 5 hospitals in Cuenca, Ecuador, from January 2015 to February 2016. Cases fulfilled validated diagnostic criteria for NC. For each case, a neurosurgical patient who did not fulfill the diagnostic criteria for NC was selected as a control. CT and MRI, as well as a CSF sample, were collected from both cases and controls...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28105459/mog-antibody-positive-benign-unilateral-cerebral-cortical-encephalitis-with-epilepsy
#2
Ryo Ogawa, Ichiro Nakashima, Toshiyuki Takahashi, Kimihiko Kaneko, Tetsuya Akaishi, Yoshiki Takai, Douglas Kazutoshi Sato, Shuhei Nishiyama, Tatsuro Misu, Hiroshi Kuroda, Masashi Aoki, Kazuo Fujihara
OBJECTIVE: To describe the features of adult patients with benign, unilateral cerebral cortical encephalitis positive for the myelin oligodendrocyte glycoprotein (MOG) antibody. METHODS: In this retrospective, cross-sectional study, after we encountered an index case of MOG antibody-positive unilateral cortical encephalitis with epileptic seizure, we tested for MOG antibody using our in-house, cell-based assay in a cohort of 24 consecutive adult patients with steroid-responsive encephalitis of unknown etiology seen at Tohoku University Hospital (2008-2014)...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28101520/an-observational-study-of-alemtuzumab-following-fingolimod-for-multiple-sclerosis
#3
Mark Willis, Owen Pearson, Zsolt Illes, Tobias Sejbaek, Christian Nielsen, Martin Duddy, Kate Petheram, Caspar van Munster, Joep Killestein, Clas Malmeström, Emma Tallantyre, Neil Robertson
OBJECTIVE: To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS: Patients with relapsing MS treated sequentially with fingolimod then alemtuzumab who experienced significant subsequent disease activity were identified by personal communication with 6 different European neuroscience centers. RESULTS: Nine patients were identified...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28101519/delayed-tacrolimus-leukoencephalopathy-a-rare-and-reversible-cause-of-dementia
#4
Diego Barragán-Martínez, Ana Simarro-Díaz, Patricia Calleja-Castaño, Aurelio Hernández-Laín, Ana Ramos-González, Alberto Villarejo-Galende
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28054001/aquaporin-4-antibody-titration-in-nmo-patients-treated-with-rituximab-a-retrospective-study
#5
Paola Valentino, Fabiana Marnetto, Letizia Granieri, Marco Capobianco, Antonio Bertolotto
OBJECTIVE: We undertook an observational retrospective study to investigate the usefulness of aquaporin-4 (AQP4) antibodies (Ab) titration in the management of patients with neuromyelitis optica (NMO) treated with rituximab (RTX) by studying (1) the correlation between AQP4-Ab titer and disease activity, (2) the influence of RTX on antibody levels, and (3) the association between AQP4-Ab levels and responsiveness to RTX. METHODS: A cell-based assay was used for AQP4-Ab titration in 322 serum samples from 7 patients with NMO treated with RTX (median follow-up 65 months), according to a treatment-to-target approach...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28054000/a-comparative-study-of-cidp-in-a-cohort-of-hiv-infected-and-hiv-uninfected-patients
#6
Kaminie Moodley, Pierre L A Bill, Vinod Bhagu Patel
OBJECTIVE: To investigate differences in clinical presentation, electrodiagnostic measures, CSF changes, and treatment outcome measures in HIV-infected and HIV-uninfected patients with chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: A retrospective analysis of medical records of all patients meeting the European Federation of Neurology diagnostic criteria for idiopathic CIDP was performed in 2 neuromuscular units in Kwa-Zulu Natal between 2003 and 2015...
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27957509/characteristics-and-pharmacodynamics-of-severe-neuroinflammation-in-a-child-with-neurolupus
#7
Michael R Pranzatelli, Nathan R McGee, Zeng Y Wang, Brajesh K Agrawal
No abstract text is available yet for this article.
March 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28053999/b-cell-populations-discriminate-between-pediatric-and-adult-onset-multiple-sclerosis
#8
Alexander Schwarz, Bettina Balint, Mirjam Korporal-Kuhnke, Sven Jarius, Kathrin von Engelhardt, Alexandra Fürwentsches, Cornelia Bussmann, Friedrich Ebinger, Brigitte Wildemann, Jürgen Haas
OBJECTIVE: To comparatively assess the B-cell composition in blood and CSF of patients with pediatric-onset multiple sclerosis (pedMS) and adult-onset multiple sclerosis (adMS). METHODS: In this cross-sectional study, we obtained blood and CSF samples from 25 patients with pedMS (8-18 years) and 40 patients with adMS (23-65 years) and blood specimens from 66 controls (1-55 years). By using multicolor flow cytometry, we identified naive, transitional, isotype class-switched memory, nonswitched memory, and double-negative memory B-cell subsets as well as plasmablasts (PB) and terminally differentiated plasma cells (PC)...
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28018945/comprehensive-population-based-determination-of-pediatric-multiple-sclerosis-health-care-costs
#9
Melissa A Wright, E Kent Korgenski, Tyler Bardsley, Joshua L Bonkowsky, Meghan S Candee
OBJECTIVE: To determine the health care costs associated with pediatric multiple sclerosis (MS). METHODS: We performed a retrospective analysis of all patients with MS 18 years of age or younger who were diagnosed or treated between 2002 and 2012 in a population-based cohort. Demographics and health care costs were extracted from the Intermountain Healthcare Enterprise Data Warehouse. Patients were divided into high-cost (>84th percentile) and low-cost groups and differences in health care utilization between the groups were analyzed...
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28018944/finding-nmo
#10
EDITORIAL
Richard Daneman
No abstract text is available yet for this article.
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/28018943/effects-of-neuromyelitis-optica-igg-at-the-blood-brain-barrier-in-vitro
#11
Yukio Takeshita, Birgit Obermeier, Anne C Cotleur, Simona F Spampinato, Fumitaka Shimizu, Erin Yamamoto, Yasuteru Sano, Thomas J Kryzer, Vanda A Lennon, Takashi Kanda, Richard M Ransohoff
OBJECTIVE: To address the hypothesis that physiologic interactions between astrocytes and endothelial cells (EC) at the blood-brain barrier (BBB) are afflicted by pathogenic inflammatory signaling when astrocytes are exposed to aquaporin-4 (AQP4) antibodies present in the immunoglobulin G (IgG) fraction of serum from patients with neuromyelitis optica (NMO), referred to as NMO-IgG. METHODS: We established static and flow-based in vitro BBB models incorporating co-cultures of conditionally immortalized human brain microvascular endothelial cells and human astrocyte cell lines with or without AQP4 expression...
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27990459/paraneoplastic-cerebellar-ataxia-with-central-hypoventilation
#12
Amy Kunchok, David Barnes, Michael Boyer, G Michael Halmagyi
No abstract text is available yet for this article.
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27957508/neurochondrin-is-a-neuronal-target-antigen-in-autoimmune-cerebellar-degeneration
#13
Ramona Miske, Catharina C Gross, Madeleine Scharf, Kristin S Golombeck, Marvin Hartwig, Urvashi Bhatia, Andreas Schulte-Mecklenbeck, Kathrin Bönte, Christine Strippel, Ludger Schöls, Matthis Synofzik, Hubertus Lohmann, Inga Madeleine Dettmann, Michael Deppe, Swantje Mindorf, Tobias Warnecke, Yvonne Denno, Bianca Teegen, Christian Probst, Stefanie Brakopp, Klaus-Peter Wandinger, Heinz Wiendl, Winfried Stöcker, Sven G Meuth, Lars Komorowski, Nico Melzer
OBJECTIVE: To report on a novel neuronal target antigen in 3 patients with autoimmune cerebellar degeneration. METHODS: Three patients with subacute to chronic cerebellar ataxia and controls underwent detailed clinical and neuropsychological assessment together with quantitative high-resolution structural MRI. Sera and CSF were subjected to comprehensive autoantibody screening by indirect immunofluorescence assay (IFA) and immunoblot. Immunoprecipitation with lysates of hippocampus and cerebellum combined with mass spectrometric analysis was used to identify the autoantigen, which was verified by recombinant expression in HEK293 cells and use in several immunoassays...
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27957507/antibodies-to-inositol-1-4-5-triphosphate-receptor-1-in-patients-with-cerebellar-disease
#14
Penelope Fouka, Harry Alexopoulos, Ioanna Chatzi, Skarlatos G Dedos, Martina Samiotaki, George Panayotou, Panagiotis Politis, Athanasios Tzioufas, Marinos C Dalakas
OBJECTIVE: To describe newly identified autoantibodies associated with cerebellar disorders. DESIGN/METHODS: We first screened the sera of 15 patients with cerebellar ataxia, without any known associated autoantibodies, with immunocytochemistry on mouse brain. After characterization and validation of a newly identified antibody, 85 additional patients with suspected autoimmune cerebellar disease were screened using a cell-based assay. RESULTS: Immunoglobulin G from one of the first 15 patients demonstrated a distinct staining pattern on Purkinje neurons...
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27900347/isolated-dysphagia-as-initial-sign-of-anti-iglon5-syndrome
#15
Jens Burchard Schröder, Nico Melzer, Tobias Ruck, Anna Heidbreder, Ilka Kleffner, Ralf Dittrich, Paul Muhle, Tobias Warnecke, Rainer Dziewas
OBJECTIVE: To report on dysphagia as initial sign in a case of anti-IgLON5 syndrome and provide an overview of the current literature. METHODS: The diagnostic workup included cerebral MRI, fiber optic endoscopic evaluation of swallowing (FEES) with the FEES tensilon test, a videofluoroscopic swallowing study, evoked potentials and peripheral nerve conduction studies, polysomnography, lumbar puncture, and screening for neural autoantibodies. A systematic review of all published cases of IgLON5 syndrome is provided...
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27844040/paroxysmal-sneezing-in-nmosd-further-evidence-of-the-localization-of-the-human-sneeze-center
#16
A Sebastian López-Chiriboga, Josephine F Huang, Eoin P Flanagan, William P Cheshire
No abstract text is available yet for this article.
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27844038/asymptomatic-cns-demyelination-related-to-tnf-%C3%AE-inhibitor-therapy
#17
Farwa Ali, Ruple S Laughlin
No abstract text is available yet for this article.
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27833932/targeted-treatment-of-brainstem-neurohistiocytosis-guided-by-urinary-cell-free-dna
#18
David Hunt, Paul Milne, Peter Fernandes, Venetia Bigley, Matthew Collin
OBJECTIVE: To identify a treatment-responsive BRAF(V600E) mutation in brainstem neurohistiocytosis, where no lesional tissue was readily obtainable, using a cell-free DNA approach. METHODS: Cell-free DNA was extracted from urine and allele-specific PCR for the BRAF(V600E) mutation was performed. Response to conventional treatment (corticosteroids and interferon) and targeted treatment with a BRAF inhibitor was assessed by clinical evaluation, gadolinium-enhanced MRI brain scan, and serial testing of urinary cell-free DNA for mutant alleles...
January 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27868081/blood-brain-barrier-integrity-intrathecal-immunoactivation-and-neuronal-injury-in-hiv
#19
Birgitta Anesten, Aylin Yilmaz, Lars Hagberg, Henrik Zetterberg, Staffan Nilsson, Bruce J Brew, Dietmar Fuchs, Richard W Price, Magnus Gisslén
OBJECTIVE: Although blood-brain barrier (BBB) impairment has been reported in HIV-infected individuals, characterization of this impairment has not been clearly defined. METHODS: BBB integrity was measured by CSF/plasma albumin ratio in this cross-sectional study of 631 HIV-infected individuals and 71 controls. We also analyzed CSF and blood HIV RNA and neopterin, CSF leukocyte count, and neurofilament light chain protein (NFL) concentrations. The HIV-infected participants included untreated neuroasymptomatic patients, patients with untreated HIV-associated dementia (HAD), and participants on suppressive antiretroviral treatment (ART)...
December 2016: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/27844039/increased-prevalence-of-autoimmune-disease-within-c9-and-ftd-mnd-cohorts-completing-the-picture
#20
Zachary A Miller, Virginia E Sturm, Gamze Balci Camsari, Anna Karydas, Jennifer S Yokoyama, Lea T Grinberg, Adam L Boxer, Howard J Rosen, Katherine P Rankin, Maria Luisa Gorno-Tempini, Giovanni Coppola, Daniel H Geschwind, Rosa Rademakers, William W Seeley, Neill R Graff-Radford, Bruce L Miller
OBJECTIVE: To determine the prevalence of autoimmune disease in symptomatic C9ORF72 (C9) mutation carriers and frontotemporal dementia with motor neuron disease (FTD/MND) cohorts. METHODS: In this case-control study, we reviewed the clinical histories of 66 patients with FTD/MND and 57 symptomatic C9 carriers (24 overlapping cases), a total of 99 charts, for history of autoimmune disease. The prevalence of autoimmune disease in C9 and FTD/MND cohorts was determined by χ(2) and Fisher exact comparisons between the combined C9 and FTD/MND group with normal control, Alzheimer disease, and progressive supranuclear palsy cohorts, as well as comparisons within C9 and FTD/MND cohorts...
December 2016: Neurology® Neuroimmunology & Neuroinflammation
journal
journal
49467
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"